Dynamic salivary cytokine profile of recurrent aphthous stomatitis patients in thalidomide maintenance treatment

Wei, Wei; Deng, Yiwen; Wang, Yufeng; Yao, Hui; Du, Guanhuan; Tang, Guoyao

doi:10.1007/s00784-024-05531-7

Cited by 2 publications

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The excessive or unopposed production of interluekine-6 (IL-6) or IL-1 plays an important role in the pathogenesis of oral aphthosis [24]. Moreover, the secretion of antiinflammatory cytokines, transforming growth factor-β (TGF-β) and IL-10 was significantly decreased in patients with RAS, indicating an imbalance in pro-and anti-inflammatory cytokines production, and hence may contribute to the development of autoimmunisation and RAS [24].…”

Section: Ras Pathogenesismentioning

confidence: 99%

A Novel Therapeutic Approach of 980 nm Photobiomodulation Delivered with Flattop Beam Profile in Management of Recurrent Aphthous Stomatitis in Paediatrics and Adolescents—A Case Series with 3-Month Follow-Up

Hanna,

Miron,

Benedicenti

2024

JCM

View full text Add to dashboard Cite

Background/Objectives: Recurrent aphthous stomatitis (RAS) is one of the most common oral mucosal lesions and a very debilitating lesion, especially in paediatric and adolescent patients. The current pharmacotherapy offers a pain relief but not without side effects, and therefore photobiomodulation (PBM) can be an alternative therapy. To the authors’ best knowledge, no published study has explored the efficacy of λ 980 nm laser PBM in the management of all RAS subtypes in paediatric and adolescent patients, and therefore, this prospective observational clinical study was conducted to bridge this gap by evaluating λ 980 nm laser PBM efficacy in symptomatic RAS management in paediatric and adolescent patients. The objectives were to evaluate (1) pain intensity alleviation; (2) wound healing rate; (3) wound size closure; (4) a complete resolution; (5) evidence of recurrence; and (6) patients’ treatment satisfaction. Methods: The study’s variables were assessed at the following timepoints: T0: pre-treatment; T1: immediately after first PBM session; T2: 5 hours (h) post first PBM session (via telephone call); T3: immediately after second PBM session (three days post first PBM session); T4: three-day follow-up (after complete PBM treatments); T5: two-week follow-up; and T6: three-month follow-up. The following PBM dosimetry and treatment protocols were employed: λ 980 nm; 300 mW; 60 s; 18 J; CW; flattop beam profile of 1 cm2 spot size; 18 J/cm2; and twice-a-week irradiation (72 h interval). Results: At T1, significant immediate pain intensity relief was reported. 33.33% recorded “4” and 66.67% reported “5” on the quantitative numeric pain intensity scale (NPIS), and this continued to improve significantly (83.33%) at T2. All the subjects reported “0” on the NPIS at T3, T4, T5 and T6. There was a significant reduction in the lesion surface area (>50% complete healing) at T3 compared to T0. Complete healing (100%) with no evidence of scarring and lesion recurrence observed at T4, T5 and T6. Very good patients’ satisfaction was reported at all timepoints. Conclusions: This is the first report demonstrating λ980 nm efficacy in all RAS subtype management in paediatric and adolescent patients with a 3-month follow-up, whereby its PBM dosimetry and treatment protocols were effective from scientific and practical standpoints, and hence multicentre RCTs with large data are warranted to validate its reproducibility and to enrich the knowledge of PBM application in all RAS subtypes.

show abstract

Section: Ras Pathogenesismentioning

confidence: 99%